Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
Inspire Medical Systems officer John Rondoni sold 2,641 shares of Common Stock in an open-market transaction at a weighted average price of $43.28 per share. The shares were sold on May 15, 2026, and he now directly holds 27,165 shares.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice relating to proposed resale of restricted common stock that vested under a registered plan. The filing lists specific vested lots: 571 shares on 02/09/2026, 1,105 shares on 02/13/2026, and 965 shares on 02/20/2026, each described as "restricted stock vesting under a registered plan."
The filing also reports a sale by John Rondoni of 700 shares on 05/14/2026 with an amount shown of $30,106.02 in the "Securities Sold During The Past 3 Months" section.
Inspire Medical Systems, Inc. officer John Rondoni reported an open-market sale of 700 shares of Common Stock. The shares were sold at a weighted average price of $43.01 per share, with individual trades ranging from $43.00 to $43.03. After this transaction, he directly owns 29,806 shares.
Inspire Medical Systems: Wellington Management Group submitted Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 2,535,954 shares of Common Stock, representing 8.81% of the class. The cover information lists the ownership figures and shared voting and dispositive powers as shown as of 03/31/2026.
Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and James E. Flynn filed an amended Schedule 13G/A reporting beneficial ownership in Inspire Medical Systems, Inc.
The filing states each Reporting Person beneficially owned 1,296,862 shares (4.50% of class). As of March 31, 2026, the Reporting Persons beneficially owned 2,703,238 shares (9.38%). The filing further states that as of May 14, 2026 the Reporting Persons ceased to beneficially own more than 5.0% of the outstanding ordinary shares.
INSP: A Form 144 notice reports a proposed sale of 700 shares of Common Stock tied to restricted stock vesting under a registered plan on 02/20/2026. The filing lists Morgan Stanley Smith Barney LLC in the broker/agent details and indicates the securities trade on the NYSE.
Inspire Medical Systems director Shawn McCormick reported an open-market sale of 696 shares of Common Stock at $45.31 per share. After this sale, he holds 27,712 shares directly. A separate entry shows an additional 3,000 shares held indirectly by trust, reflecting estate or planning-related ownership.
Inspire Medical Systems, Inc. reported results from its 2026 annual stockholder meeting and related governance and compensation changes. Stockholders approved an amended and restated 2018 Incentive Award Plan authorizing 9,903,857 common shares for awards, including 2,600,000 additional shares, and added one-year minimum vesting, tighter dividend rules on unvested awards, and extended the plan through March 6, 2036.
Investors also approved an amendment to the certificate of incorporation to phase out the classified board structure and move to annual director elections beginning with the 2029 annual meeting. All proposals on the ballot, including director elections, auditor ratification, executive pay on an advisory basis, and a potential adjournment authority, received sufficient support. Approximately 25,287,595 shares, about 88% of outstanding common stock, were represented at the meeting.
Ellis Gary Lee reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems, Inc. director Ellis Gary Lee reported receiving an equity award of 3,562 shares of common stock in the form of Restricted Stock Units (RSUs) at no cash purchase price. Each RSU represents the right to receive one share upon vesting, which occurs on the earlier of the first anniversary of the grant date or immediately before a Change of Control under the company’s 2018 Incentive Award Plan, subject to continued service. Following this grant, Lee directly holds 10,838 shares of common stock.